NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT02523313,Immunotherapy With Nivolumab or Nivolumab Plus Ipilimumab vs. Double Placebo for Stage IV Melanoma w. NED,https://clinicaltrials.gov/study/NCT02523313,,COMPLETED,"This is a prospective, double-blind placebo-controlled, multicenter, randomized phase II trial testing the adjuvant immunotherapy with Nivolumab plus Ipilimumab Placebo or Nivolumab plus Ipilimumab versus Double Placebo Control as a post-surgical/post-radiation treatment for stage IV melanoma with no evidence of disease (NED).",NO,Malignant Melanoma,DRUG: Nivolumab + Placebo|DRUG: Nivolumab + Ipilimumab|DRUG: Double Placebo Control,"Efficacy of adjuvant immunotherapy with Nivolumab alone or in combination with Ipilimumab (Recurrence-free survival), Recurrence-free survival (RFS) defined as the time from date of randomization until the date of the first recurrence (local or distant metastasis), new primary melanoma or death from any cause, whichever occurs first., 24 months after the last patient ended treatment","Overall survival (OS), The OS of a patient is defined as the time from date of randomization until date of death., 24 months after the last patient ended treatment|Time to recurrence (TTR), The TTR of a patient is defined as the time from date of randomization until date of disease recurrence (local or distant metastasis) or melanoma-related death., 24 months after the last patient ended treatment|Progression/recurrence free survival 2 (PRFS2) for crossover patients of Arm C, The PRFS2 is defined as time from date of randomization until the date of first disease progression per RECIST 1.1 beyond the initial unresectable disease recurrence, the date of second recurrence in patients without evidence of disease after surgery of a resectable first recurrence or the date of death, whichever occurs first., 24 months after the last patient ended treatment","Safety / Toxicity All adverse events ≥ Grade 3 according to CTCAE Version 4.0 criteria, All adverse events ≥ Grade 3 according to CTCAE Version 4.0 criteria, that are related to the administration of the investigational agents will be assessed, until 90 days after discontinuation of dosing",Prof. Dr. med. Dirk Schadendorf,,ALL,"ADULT, OLDER_ADULT",PHASE2,167,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",IMMUNED,2015-09-02,2021-06-27,2021-06-27,2015-08-14,,2021-12-13,"Charité Berlin, Berlin, 10117, Germany|Elbe Klinikum Buxtehude, Buxtehude, 21614, Germany|Universitätsklinikum Dresden, Dresden, 01307, Germany|HELIOS Klinikum Erfurt, Erfurt, 99089, Germany|Studienzentrum Hautklinik Universitätsklinikum Essen (AöR) Klinik für Dermatologie, Essen, 45147, Germany|SRH Wald-Klinikum Gera GmbH, Gera, 07548, Germany|Medizinische Hochschule Hannover, Hannover, 30625, Germany|Universitätrsklinikum Heidelberg Dermatologie / NCT, Heidelberg, 69120, Germany|SLK Kliniken Heilbronn GmbH, Heilbronn, 74078, Germany|Universitäts-Hautklinik Kiel Klinik f. Dermatologie, Venerologie u. Allergologie, Kiel, 24105, Germany|Universitätsklinikum Leipzig Klinik u. Poliklinik f. Dermatologie, Venerologie u. Allergologie, Leipzig, 04103, Germany|Klinikum der Stadt Ludwigshafen, Ludwigshafen, 67063, Germany|UKSH Campus Lübeck, Lübeck, 23538, Germany|Universitätsklinikum Mainz Hautklinik und Polklinik, Mainz, 55131, Germany|Klinik für Dermatologie, Venerologie und Allergologie UMM - Universitätsmedizin Mannheim, Mannheim, 68167, Germany|Johannes Wesling Klinikum Minden Hautklinik, Minden, 32429, Germany|Universitätsklinikum München (LMU), München, 80337, Germany|Fachklinik Hornheide, Münster, 48157, Germany|Universitätsklinikum Regensburg, Regensburg, 93053, Germany|Universitätshautklinik Tübingen, Tübingen, 72076, Germany",
